European Companies Search Engine
EU funding (€150,000): Highly multiplexed, quantitative protein biomarker profiling (hmqPro) Hor1 Jul 2022 EU Research and Innovation programme "Horizon"
Overview
Text
Highly multiplexed, quantitative protein biomarker profiling (hmqPro)
The project will develop a multipurpose, highly multiplexed, quantitative protein profiling (hmqPro) platform that can be adapted to a wide range of applications, particularly biomarker discovery. Biomarkers are a 43 Billion USD market spanning applications in diagnostics, drug discovery & development, personalized medicine, disease risk assessment. The method comprises an antibody-based profiling of a large number of proteins or protein posttranslational modifications against a large number of samples irrespective of source. Unlike competitor methods, hmqPro does not require platform-specific assay or detection equipment. Dual multiplexing implemented in a variant method, hmqPro-2D, will make the platform competitive against existing protein profiling methods in per-assay cost, flexibility and scalability. The hmqPro platform uniquely complements the technology portfolio of Epigenica AB and we will chart out two commercialization routes: first, hmqPro will be integrated into a service laboratory offering high-throughput sample-to-result epigenome and protein profiling services to academia, pharma and biotech industries. Second, we will package the method in a kit format distributed to R&D and clinical end users. In summary, the proposed project will deliver a new quantitative protein profiling platform that will have the capacity to impact the biomarker discovery market by combining unique flexibility with high-throughput.
Funded Companies:
| Company name | Funding amount |
| Epigenica AB | €120,000 |
| Karolinska Institutet | €30,000 |
Source: https://cordis.europa.eu/project/id/101069454
The filing refers to a past date, and does not necessarily reflect the current state.
